iOnctura, a UK-based biotech company, is making significant strides in the field of oncology under the leadership of CEO Catherine Pickering. The company is focused on developing innovative therapies for challenging cancer types, including highly fibrotic tumors and uveal melanoma.
iOnctura’s lead asset, roginolisib, is a small molecule a first-in-class allosteric modulator of PI3Kδ currently in four Phase II studies. Originally developed by Merck for lupus, it is now being explored for its potential in oncology, particularly for its ability to inhibit the PI3K delta pathway.
This pathway is crucial for cancer cell survival and proliferation. Roginolisib has shown promising results in preclinical and early clinical trials, demonstrating significant efficacy and safety.
While initially focused on uveal melanoma, the company is now expanding the indications for roginolisib to include both solid and hematological tumors. The drug’s unique mechanism of action, which enhances immune response while reducing immunosuppression, makes it a versatile candidate for various cancer types.
In addition to roginolisib, iOnctura is developing cambritaxestat, a small molecule drug targeting highly fibrotic tumors. This drug works by inhibiting the enzyme autotaxin, which plays a role in tumor fibrosis and immune evasion. Early data from preclinical studies suggest that the asset could be effective in treating gastrointestinal cancers, including pancreatic cancer.
iOnctura recently raised €86m in a Series B financing round, which will support the continued development of its clinical pipeline. The company aims to launch its lead asset in uveal melanoma within the next few years and is also exploring potential collaborations and partnerships to expand its reach in the oncology market.
Timestamps:
Introduction and overview of iOnctura - 00:08
Progress of lead asset roginolisib - 00:38
Challenges and advantages of PI3K delta inhibition - 03:09
Expansion to multiple indications - 08:12
Development of cambritaxestat - 16:17
Future prospects and financing - 24:22
Long-term goals and company vision - 30:25
